Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service？ Thank you for choosing ACROBiosystems. Would you rate our product and service？
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
Flow cytometric analysis of Anti-CD19 CAR-293 cells staining with 100 μL of 20 μg/mL Human CD19 (20-291) Protein, Fc Tag, low endotoxin (Cat. No. CD9-H5259) and negative control protein respectively, washed and then followed with PE-Labeled Mouse-Anti-Human-IgG Antibody, Mouse IgG1 (6F11C8) (Cat. No. IGG-PFY69) at 1:50 dilution (2 μL of the antibody stock solution corresponds to labeling of 1e6 cells in a final volume of 100 µL) and analyzed with FACS. PE signal was used to evaluate the binding activity (QC tested).
Immobilized Human TNF-alpha Protein, His Tag (Cat. No. TNA-H5228) at 2 μg/mL (100 μL/well) can bind Human Monoclonal Anti-TNF-alpha antibody, Human IgG1 (16H5) (Cat. No. TNA-AM494) when detected by HRP conjugated Anti-Human-IgG-Fc Antibody (6F11C8),mAb (Cat. No. IGG-LY69) dilute at 1:10000 (0.0842μg/ml) (QC tested).
Immobilized Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG1 (AM359b) (Cat. No. SPD-M265) at 1 μg/mL (100 μL/well) can bind Biotinylated Monoclonal Mouse Anti-Human-IgG Antibody, Mouse IgG1 (6F11C8) (Cat. No. IGG-BLY69) with a linear range of 0.2-16 ng/mL (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Imlifidase | Mac-1 | Approved | Hansamed Inc | Idefirix | EU | Rejection of renal transplantation | Hansa Biopharma Ab | 2020-08-25 | Rejection of renal transplantation; Kidney Diseases; Purpura, Thrombotic Thrombocytopenic; Rejection of organ transplantation; Renal Insufficiency, Chronic; Guillain-Barre Syndrome; Kidney Failure, Chronic | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Ricefidase | KJ-103; KJ103 | Phase 3 Clinical | Shanghai Bao Pharmaceuticals Co Ltd | Rejection of renal transplantation; Anti-Glomerular Basement Membrane Disease | Details |
| AT-02 | AT-02 | Phase 2 Clinical | Attralus Inc | Immunoglobulin Light-chain Amyloidosis; Amyloidosis | Details |
| BHV-1300 | BHV-1300 | Phase 1 Clinical | Biohaven Pharmaceuticals Inc | Arthritis, Rheumatoid | Details |
| HNSA-5487 | HNSA 5487; HNSA-5487 | Phase 1 Clinical | Hansa Biopharma Ab | Neoplasms; Autoimmune Diseases | Details |
| Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD) | Phase 1 Clinical | University Of California San Diego | Leukemia, Myeloid, Acute | Details |
This web search service is supported by Google Inc.
アクロバイオシステムズの公式アカウント
A-Z
